Thrombin receptor antagonists

ABSTRACT

Heterocyclic-substituted tricyclics of the formula  
                 
or a pharmaceutically acceptable salts thereof, wherein: 
         n 1  and n 2  are independently 0-2; Het is an optionally substituted mono-, bi- or tricyclic heteroaromatic group; B is alkyl or optionally substituted alkenyl;    R 22  is —COR 23  or a carboxy, sulfinyl, sulfonyl, sulfonamide or amino acid derivative;    R 23  is haloalkyl; alkenyl; haloalkenyl; alkynyl; optionally substituted cycloalkyl; cycloalkyl-alkyl; aryl; arylalkyl; heteroaryl; heterocycloalkyl; or —COOH and/or —SO 3 H substituted alkyl;    R 1 , R 2 , R 3 , R 9 , R 10  and R 11  are as defined in the specification; are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds.

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Ser. No. 10/271,715 filed onOct. 16, 2002, which claims the benefit of U.S. Provisional Application60/330,359, filed Oct. 18, 2001.

BACKGROUND OF THE INVENTION

Thrombin is known to have a variety of activities in different celltypes and thrombin receptors are known to be present in such cell typesas human platelets, vascular smooth muscle cells, endothelial cells andfibroblasts. It is therefore expected that thrombin receptor antagonistswill be useful in the treatment of thrombotic, inflammatory,atherosclerotic and fibroproliferative disorders, as well as otherdisorders in which thrombin and its receptor play a pathological role.

Thrombin receptor antagonist peptides have been identified based onstructure-activity studies involving substitutions of amino acids onthrombin receptors. In Bernatowicz et al, J. Med. Chem., 39 (1996), p.4879-4887, tetra- and pentapeptides are disclosed as being potentthrombin receptor antagonists, for exampleN-trans-cinnamoyl-p-fluoroPhe-p-guanidinoPhe-Leu-Arg-NH₂ andN-trans-cinnamoyl-p-fluoroPhe-p-guanidinoPhe-Leu-Arg-Arg-NH₂. Peptidethrombin receptor anatgonists are also disclosed in WO 94/03479,published Feb. 17, 1994.

Cannabinoid receptors belong to the superfamily of G-protein coupledreceptors. They are classified into the predominantly neuronal CB,receptors and the predominantly peripheral CB₂ receptors. Thesereceptors exert their biological actions by modulating adenylate cyclaseand Ca⁺² and K⁺ currents. While the effects of CB₁ receptors areprincipally associated with the central nervous system, CB₂ receptorsare believed to have peripheral effects related to bronchialconstriction, immunomodulation and inflammation. As such, a selectiveCB₂ receptor binding agent is expected to have therapeutic utility inthe control of diseases associated with rheumatoid arthritis, systemiclupus erythematosus, multiple sclerosis, diabetes, osteoporosis, renalischemia, cerebral stroke, cerebral ischemia, nephritis, inflammatorydisorders of the lungs and gastrointestinal tract, and respiratory tractdisorders such as reversible airway obstruction, chronic asthma andbronchitis (R. G. Pertwee, Curr. Med. Chem. 6(8), (1999), 635).

Himbacine, a piperidine alkaloid of the formula

has been identified as a muscarinic receptor antagonist. The totalsynthesis of (+)-himbacine is disclosed in Chackalamannil et al, J. Am.Chem Soc., 118 (1996), p. 9812-9813.

SUMMARY OF THE INVENTION

The present invention relates to thrombin receptor antagonistsrepresented by the formula I

or a pharmaceutically acceptable salt thereof, wherein:

R is 1 to 3 substituents independently selected from the groupconsisting of H, C₁-C₆ alkyl, halogen, hydroxy, amino,(C₁-C₆)alkyl-amino, (C₁-C₆)-dialkylamino, (C₁-C₆)alkoxy, —COR¹⁶,—COOR¹⁷, —SOR¹⁶, —SO₂R¹⁶, —SO₂NR¹⁷R¹⁸, —NR¹⁷SO₂R¹⁸, NR¹⁶COR^(16a),NR¹⁶COOR^(16a), —NR¹⁶CONR⁴R⁵, fluoro-(C₁-C₆)alkyl, difluoro(C₁-C₆)alkyl,trifluoro(C₁-C₆)alkyl, C₃-C₆ cycloalkyl, aryl(C₁-C₆)alkyl,hydroxy(C₁-C₆)alkyl, amino-(C₁-C₆)-alkyl, aryl and thio(C₁-C₆)alkyl;

R¹ and R² are independently selected from the group consisting of H,C₁-C₆ alkyl, fluoro(C₁-C₆)alkyl, difluoro(C₁-C₆)alkyl,trifluoro-(C₁-C₆)alkyl, C₃-C₆ cycloalkyl, C₂-C₆ alkenyl,aryl(C₁-C₆)alkyl, hydroxy-(C₁-C₆)alkyl, amino(C₁-C₆)alkyl, aryl andthio(C₁-C₆)alkyl; or R¹ and R² together form an ═O group;

R³ is H, hydroxy, C₁-C₆alkoxy, aryloxy, aryl(C₁-C₆)alkyloxy,heteroaryloxy, heteroaryl(C₁-C₆)alkyloxy, (C₃-C₆)cycloalkyloxy, —SOR¹⁶,—SO₂R¹⁷, —SO₂NR¹⁸R¹⁹, —SR¹⁸, —SO₃H, —C(O)OR¹⁷, —C(O)NR¹⁸R¹⁹, —OC(O)R³²,—OC(O)NR³³R³⁴—(CR³³R³⁴)_(n)OR³², —NR⁴R⁵, —NR³³COOR³², —NR³³COR³²,—NR³³S(O)₂R³², —NR³³CONR³³R³⁴, —NR³³S(O)₂NR³³R³⁴, —(CR³³R³⁴)_(n)NR⁴R⁵,—(CR³³R³⁴)_(n)NR³³COOR³², —(CR³³R³⁴)_(n)NR³³COR³², —(CR³³R³⁴)_(n)NR³³S(O)₂R³², —(CR³³R³⁴)_(n)NR³³CONR³³R³⁴,—(CR³³R³⁴)_(n)NR³³S(O)₂NR³³R³⁴, (C₁-C₆)alkyl, halogen, C₃-C₆ cycloalkyl,C₂-C₆ alkenyl, —CN, aryl, heteroaryl, heterocycloalkyl, —P(O)(OR⁷)₂ or(C₁-C₆)alkyl substituted by 1 to 3 substituents independently selectedfrom the group consisting of halogen, —OH, —NH₂, aryl, —COOH, —SO₃H,thio and (C₁-C₆)alkylthio;

n is 1, 2, 3 or 4;

n1 and n2 are independently 0-3, provided both are not 0;

Het is a mono-, bi- or tricyclic heteroaromatic group of 5 to 14 atomscomprised of 1 to 13 carbon atoms and 1 to 4 heteroatoms independentlyselected from the group consisting of N, O and S, wherein a ringnitrogen can form an N-oxide or a quaternary group with a C₁-C₄ alkylgroup, wherein Het is attached to B by a carbon atom ring member, andwherein the Het group is substituted by 1 to 4 substituents, W,independently selected from the group consisting of C₁-C₆ alkyl;

—NR⁴R⁵; —NHCOR²⁶; —NHSO₂R¹⁶;

R²¹-aryl; aryl wherein adjacent carbons form a ring with amethylenedioxy group; and R²¹-heteroaryl;

R⁴ and R⁵ are independently selected from the group consisting of H,C₁-C₆ alkyl, phenyl, benzyl and C₃-C₆ cycloalkyl, or R⁴ and R⁵ togetherare —(CH₂)₃—, —(CH₂)₄—, —(CH₂)₅— or —(CH₂)₂NR⁷—(CH₂)₂— and form a ringwith the nitrogen to which they are attached;

R⁷ is H or (C₁-C₆)alkyl;

R⁸, R¹⁰ and R¹¹ are independently selected from the group consisting ofR¹ and —OR¹;

R⁹ is H, OH, —NR⁴R⁵, C₁-C₆alkoxy, halogen or halo(C₁-C₆)alkyl;

B is —(CH₂)_(n) ₃ — or cis or trans —(CH₂)_(n4)CR¹²═CR^(12a)(CH₂)_(n) ₅, wherein n₃ is 0-5, n₄ and n₅ are independently 0-2, and R¹² andR^(12a) are independently selected from the group consisting of H, C₁-C₆alkyl and halogen;

R¹⁶ and R^(16a) are independently selected from the group consisting ofC₁-C₆ alkyl, phenyl and benzyl;

R¹⁷, R¹⁸ and R¹⁹ are independently selected from the group consisting ofH, C₁-C₆alkyl, phenyl and benzyl;

R²¹ is 1 to 3 substituents independently selected from the groupconsisting of H, —CF₃, —OCF₃, halogen, —NO₂, —CN, C₁-C₆ alkyl, C₁-C₆alkoxy, —NH₂, (C₁-C₆)-alkyl-amino, di-((C₁-C₆)alkyl)amino,amino(C₁-C₆)alkyl, (C₁-C₆)-alkylamino(C₁-C₆)alkyl,di-((C₁-C₆)alkyl)-amino(C₁-C₆)alkyl, hydroxy-(C₁-C₆)alkyl, —COOR¹⁷,—COR¹⁷, —CONR²⁴R²⁵, —NHCOR¹⁶, —NHSO₂R¹⁶, —NHSO₂CH₂CF₃, —SO₂NR²⁴R²⁵,—NR²⁹C(O)NR²⁴R²⁵, —SO₂R³⁰, —P(O)(OR²⁹)₂, aryl, aryl(C₁-C₆)alkyl,heteroaryl, heterocycloalkyl, and —CR²⁹(═NOR²⁸);

R²² is —COR²³, —S(O)R³¹, —S(O)₂R³¹, —SO₂NR²⁴R²⁵ or —COOR²⁷;

R²³ is halo(C₁-C₆)alkyl; C₂-C₆ alkenyl; halo(C₂-C₆)alkenyl; C₂-C₆alkynyl; C₃-C₇-cycloalkyl; (C₃-C₇)cycloalkyl(C₁-C₆)alkyl;(C₃-C₇)cycloalkyl substituted by 1 to 3 substituents selected from thegroup consisting of halo, (C₁-C₃)alkoxy(C₁-C₃)alkyl, hydroxy and C₁-C₆alkoxy; aryl; aryl(C₂-C₆)alkyl; heteroaryl; heterocycloalkyl;(C₁-C₆)alkyl substituted by 1-3 substituents independently selected from—COOH and —SO₃H; or

wherein R³⁵ and R³⁶ are independently selected from the group consistingof H, alkyl, or R³⁷-substituted C₁-C₆ alkyl, wherein R³⁷ is selectedfrom the group consisting of HO—, HS—, CH₂S—, —NH₂, phenyl,p-hydroxyphenyl and indolyl;

R²⁴ and R²⁵ are independently selected form the group consisting of H,C₁-C₆ alkyl, halo(C₁-C₆)alkyl, C₂-C₆ alkenyl, halo(C₂-C₆)alkyl, C₂-C₆alkynyl, aryl, aryl-(C₁-C₆)alkyl, C₃-C₇-cycloalkyl,halo(C₃-C₇)cycloalkyl, (C₁-C₃)alkoxy(C₁-C₃)-alkyl, hydroxy and C₁-C₆alkoxy;

R²⁶ is C₃-C₇-cycloalkyl, aryl, aryl-(C₁-C₆)alkyl, heteroaryl,heteroaryl-(C₁-C₆)alkyl or (C₁-C₆)alkylamino;

R²⁷ is C₁-C₆alkyl, phenyl, benzyl, (C₁-C₃)alkoxy(C₁-C₃)-alkyl,(C₃-C₇)-cycloalkyl, carboxy(C₁-C₆)alkyl, sulfo(C₁-C₆)alkyl, or(C₁-C₆)alkyl substituted by NR¹⁸R¹⁹ and carboxy;

R²⁸ is H, C₁-C₆ alkyl, phenyl, benzyl or (C₁-C₃)alkoxy(C₁-C₃)alkyl;

R²⁹ and R³⁰ are independently selected from the group consisting of Hand C₁-C₆ alkyl;

R³¹ is (C₁-C₆)alkyl; halo(C₁-C₆)alkyl; C₂-C₆ alkenyl; halo(C₂-C₆)alkyl;C₂-C₆ alkynyl; C₃-C₇-cycloalkyl; (C₃-C₇)cycloalkyl substituted by 1 to 3substituents selected from the group consisting of halo,(C₁-C₃)alkoxy(C₁-C₃)alkyl, hydroxy and C₁-C₆ alkoxy; aryl;aryl(C₁-C₆)alkyl; heteroaryl; heterocycloalkyl; (C₁-C₆)alkyl substitutedby 1-3 substituents independently selected from —COOH and —SO₃H; or(C₁-C₆)alkoxy;

R³² is R³⁵—(C₁-C₆)alkyl, R³⁵—(C₃-C₇)cycloalkyl, R³⁵—(C₂-C₆)alkenyl,R³⁵—(C₂-C₆)-alkynyl or R³⁵-aryl, wherein R³⁵ is 1 or 2 substituentsindependently selected from the group consisting of H, —COOH, —NH₂,—SO₃H, ═O and ═NOR²⁸; and

R³³ and R³⁴ are independently selected from the group consisting of H,(C₁-C₆)alkyl and C₃-C₇-cycloalkyl.

This invention also relates to a method of using a compound of formula Iin the treatment of thrombosis, atherosclerosis, restenosis, plateletaggregation, coagulation, cancer, inflammatory diseases or respiratorydiseases, comprising administering a compound of formula I to a mammalin need of such treatment. In particular, the present invention relatesto a method of using a compound of formula I in the treatment ofthrombosis, atherosclerosis, restenosis, hypertension, angina pectoris,arrhythmia, heart failure, myocardial infarction, glomerulonephritis,thrombotic stroke, thromboembolytic stroke, peripheral vasculardiseases, cerebral ischemia, cancer, rheumatoid arthritis, systemiclupus erythematosus, multiple sclerosis, diabetes, osteoporosis, renalischemia, cerebral stroke, nephritis, inflammatory disorders of thelungs and gastrointestinal tract, reversible airway obstruction, chronicasthma or bronchitis. It is contemplated that a compound of thisinvention may be useful in simultaneously treating more than one of thediseases listed.

In another aspect, the invention relates to a pharmaceutical compositioncomprising at least one compound of formula I in a pharmaceuticallyacceptable carrier.

In yet another aspect, the invention relates to the novel compoundsrepresented by the structural formula

wherein W and Z are as defined in the following table: W Z

—S—

—S(O)—

—O—

—O—

—O—

—O—

—O—

—O—

—NH—

—N(CH₃)—

DETAILED DESCRIPTION

The present invention relates to substituted tricyclic himbacinederivatives having one or more of anti-thrombotic, anti-plateletaggregation, antiatherosclerotic, antirestenotic and anti-coagulantactivity. Thrombosis-related diseases treated by the compounds of thisinvention include thrombosis, atherosclerosis, restenosis, hypertension,angina pectoris, arrhythmia, heart failure, myocardial infarction,glomerulonephritis, thrombotic and thromboembolytic stroke, peripheralvascular diseases, other cardiovascular diseases, cerebral ischemia,inflammatory disorders, neurodegenerative diseases and cancer, as wellas other disorders in which thrombin and its receptor play apathological role. Thrombin receptor antagonists are also known asprotease activated receptor (PAR) antagonists.

The compounds of the invention also bind to cannabinoid (CB2) receptorsand are useful in the treatment of inflammatory diseases or respiratorydiseases such as one or more of rheumatoid arthritis, systemic lupuserythematosus, multiple sclerosis, diabetes, osteoporosis, renalischemia, cerebral stroke, cerebral ischemia, nephritis, inflammatorydisorders of the lungs and gastrointestinal tract, and respiratory tractdisorders such as reversible airway obstruction, chronic asthma andbronchitis.

Preferred definitions of the variables in the structure of formula I areas follows:

The sum of n1 and n2 is preferably 2-3, more preferably 3. Especiallypreferred are compounds of formula I wherein n1 is 1 and n2 is 2, or n1is 0 and n2 is 3.

R is preferably 1 substituent selected from the group consisting of H,C₁-C₆ alkyl, halogen, hydroxy, amino and (C₁-C₆)alkoxy.

R¹ and R² are preferably independently selected from the groupconsisting of H and C₁-C₆ alkyl; more preferably, R¹ is C₁-C₆ alkyl andR² is H.

R³ is preferably H, hydroxy, C₁-C₆alkoxy, halogen, C₃-C₆ cycloalkyl,—CN, (C₁-C₆)alkyl, —COOR¹⁷ or —NR⁴R⁵, more preferably H, hydroxy or(C₁-C₆)alkyl.

Het is preferably pyridyl or quinolyl attached to B by a carbon atomring member, and substituted by 1 to 4 substituents selected from W.

W is preferably selected from —NR⁴R⁵, —NHCOR²⁶, —NHSO₂R¹⁶, R²¹-aryl andheteroaryl.

R⁴ and R⁵ are preferably independently selected from the groupconsisting of H, C₁-C₆ alkyl and C₃-C₆ cycloalkyl, or R⁴ and R⁵ togetherare —(CH₂)₃—, —(CH₂)₄— or —(CH₂)₅— and form a ring with the nitrogen towhich they are attached.

R⁸, R¹⁰ and R¹¹ are preferably H or (C₁-C₆)alkyl.

R⁹ is preferably H, OH or C₁-C₆alkoxy.

B is preferably trans —CH═CH—.

R¹⁶ is preferably C₁-C₆ alkyl.

R²¹ is preferably 1 to 3 substituents independently selected from thegroup consisting of H, —CF₃, —OCF₃, halogen, —CN, C₁-C₆ alkyl, C₁-C₆alkoxy, —NH₂ and —CR²⁹(═NOR²⁸).

R²² is preferably —COR²³, —S(O)₂R³¹ or —COOR²⁷.

R²³ is preferably C₃-C₇-cycloalkyl; (C₃-C₇)cyclo-alkyl substituted by 1to 3 substituents selected from the group consisting of halo,(C₁-C₃)alkoxy(C₁-C₃)alkyl, hydroxy and C₁-C₆ alkoxy;(C₃-C₇)cycloalkyl(C₁-C₆)alkyl; aryl; and aryl(C₂-C₆)alkyl. Morepreferably, R²³ is C₃-C₇-cycloalkyl; (C₃-C₇)cycloalkyl(C₁-C₆)alkyl oraryl-(C₂-C₆)alkyl, especially cyclopropyl, cyclopropylmethyl, andbenzyl.

R²⁷ is preferably C₁-C₆alkyl, phenyl, benzyl,(C₁-C₃)alkoxy(C₁-C₃)-alkyl, or (C₃-C₇)-cycloalkyl.

R²⁸ is preferably H or C₁-C₆ alkyl.

R³¹ is preferably (C₁-C₆)alkyl, C₃-C₇-cycloalkyl, aryl oraryl(C₁-C₆)alkyl, more preferably (C₁-C₆)alkyl or aryl(C₁-C₆)alkyl,especially (C₁-C₆)alkyl or benzyl.

Unless otherwise defined, the term “alkyl” or “lower alkyl” meansstraight or branched alkyl chains of 1 to 6 carbon atoms and “alkoxy”similarly refers to alkoxy groups having 1 to 6 carbon atoms.

Fluoroalkyl, difluoroalkyl and trifluoroalkyl mean alkyl chains whereinthe terminal carbon is substituted by 1, 2 or 3 fluoroatoms, e.g., —CF₃,—CH₂CF₃, —CH₂CHF₂ or —CH₂CH₂F. Haloalkyl means an alkyl chainsubstituted by 1 to 3 halo atoms.

“Alkenyl” means straight or branched carbon chains of 1 to 6 carbonatoms having one or more double bonds in the chain, conjugated orunconjugated. Similarly, “alkynyl” means straight or branched carbonchains of 1 to 6 carbon atoms having one or more triple bonds in thechain. Where an alkyl, alkenyl or alkynyl chain joins two othervariables and is therefore bivalent, the terms alkylene, alkenylene andalkynylene are used. Haloalkenyl means an alkenyl chain substituted by 1to 3 halo atoms.

“Cycloalkyl” means a saturated carbon ring of 3 to 6 carbon atoms, while“cycloalkylene” refers to a corresponding bivalent ring, wherein thepoints of attachment to other groups include all positional andstereoisomers. Halocycloalkyl means a cycloalkyl ring substituted by 1to 3 halo atoms.

“Heterocycloalkyl” as a substituent on Het means saturated rings of 4 to7 atoms comprised of 3 to 4 carbon atoms and 1 to 3 heteroatoms selectedfrom the group consisting of —O—, —S— and —NR⁷— joined to the rest ofthe molecule through a carbon atom. Examples of heterocyclo-alkyl groupsare 2-azetidinyl, 2-pyrrolidinyl, tetrahydrothiophen-2-yl,tetrahydro-2-furanyl, 4-piperidinyl, 2-piperazinyl,tetrahydro-4-pyranyl, 2-morpholinyl and 2-thiomorpholinyl.

“Halogen” refers to fluorine, chlorine, bromine or iodine radicals.

When R⁴ and R⁵ join to form a ring with the nitrogen to which they areattached, the rings formed are 1-pyrrolidinyl, 1-piperidinyl and1-piperazinyl, wherein the piperazinyl ring may also be substituted atthe 4-position nitrogen by a group R⁷.

“Dihydroxy(C₁-C₆)alkyl” refers to an alkyl chain substituted by twohydroxy groups on two different carbon atoms.

“Aryl” means phenyl, naphthyl, indenyl, tetrahydronaphthyl or indanyl.

“Heteroaryl” means a single ring, bicyclic or benzofused heteroaromaticgroup of 5 to 10 atoms comprised of 2 to 9 carbon atoms and 1 to 4heteroatoms independently selected from the group consisting of N, O andS, provided that the rings do not include adjacent oxygen and/or sulfuratoms. N-oxides of the ring nitrogens are also included, as well ascompounds wherein a ring nitrogen is substituted by a C₁-C₄ alkyl groupto form a quaternary amine. Examples of single-ring heteroaryl groupsare pyridyl, oxazolyl, isoxazolyl, oxadiazolyl, furanyl, pyrrolyl,thienyl, imidazolyl, pyrazolyl, tetrazolyl, thiazolyl, isothiazolyl,thiadiazolyl, pyrazinyl, pyrimidyl, pyridazinyl and triazolyl. Examplesof bicyclic heteroaryl groups are naphthyridyl (e.g., 1, 5 or 1,7),imidazopyridyl, pyrido[2,3]imidazolyl, pyridopyrimidinyl and7-azaindolyl. Examples of benzofused heteroaryl groups are indolyl,quinolyl, isoquinolyl, phthalazinyl, benzothienyl (i.e.,thionaphthenyl), benzimidazolyl, benzofuranyl, benzoxazolyl andbenzofurazanyl. All positional isomers are contemplated, e.g.,1-pyridyl, 2-pyridyl, 3-pyridyl and 4-pyridyl. W-substituted heteroarylrefers to such groups wherein substitutable ring carbon atoms have asubstituent as defined above, or where adjacent carbon atoms form a ringwith an alkylene group or a methylenedioxy group.

The term “Het” is exemplified by the single ring, bicyclic andbenzofused heteroaryl groups as defined immediately above, as well astricyclic groups such as benzoquinolinyl (e.g., 1,4 or 7,8) orphenanthrolinyl (e.g., 1,7; 1,10; or 4,7). Het groups are joined togroup B by a carbon ring member, e.g., Het is 2-pyridyl, 3-pyridyl or2-quinolyl.

Examples of heteroaryl groups wherein adjacent carbon atoms form a ringwith an alkylene group are 2,3-cyclopentenopyridine,2,3-cyclohexenopyridine and 2,3-cycloheptenopyridine.

When R²² is —COR²³ and R²³ is

this group is an acyl radical of an amino acid.

is a naturally occurring amino acid selected from alanine, glycine,valine, leucine, isoleucine, phenylalanine, trytophan, methionine,serine, theronine, cysteine, cystine, or tyrosine.

The above statements, wherein, for example, R⁴ and R⁵ are said to beindependently selected from a group of substituents, means that R⁴ andR⁵ are independently selected, but also that where an R⁴ or R⁵ variableoccurs more than once in a molecule, those occurrences are independentlyselected. Those skilled in the art will recognize that the size andnature of the substituent(s) will affect the number of substituentswhich can be present.

Compounds of the invention have at least one asymmetrical carbon atomand therefore all isomers, including diastereomers and rotationalisomers are contemplated as being part of this invention. The inventionincludes (+)- and (−)-isomers in both pure form and in admixture,including racemic mixtures. Isomers can be prepared using conventionaltechniques, either by reacting optically pure or optically enrichedstarting materials or by separating isomers of a compound of formula 1.

Typical preferred compounds of the present invention have the followingstereochemistry:

with compounds having that absolute stereochemistry being morepreferred.

Those skilled in the art will appreciate that for some compounds offormula 1, one isomer will show greater pharmacological activity thanother isomers.

Compounds of the invention with a basic group can form pharmaceuticallyacceptable salts with organic and inorganic acids. Examples of suitableacids for salt formation are hydrochloric, sulfuric, phosphoric, acetic,citric, oxalic, malonic, salicylic, malic, fumaric, succinic, ascorbic,maleic, methanesulfonic and other mineral and carboxylic acids wellknown to those in the art. The salt is prepared by contacting the freebase form with a sufficient amount of the desired acid to produce asalt. The free base form may be regenerated by treating the salt with asuitable dilute aqueous base solution such as dilute aqueous sodiumbicarbonate. The free base form differs from its respective salt formsomewhat in certain physical properties, such as solubility in polarsolvents, but the salt is otherwise equivalent to its respective freebase forms for purposes of the invention.

Certain compounds of the invention are acidic (e.g., those compoundswhich possess a carboxyl group). These compounds form pharmaceuticallyacceptable salts with inorganic and organic bases. Examples of suchsalts are the sodium, potassium, calcium, aluminum, lithium, gold andsilver salts. Also included are salts formed with pharmaceuticallyacceptable amines such as ammonia, alkyl amines, hydroxyalkylamines,N-methylglucamine and the like.

Compounds of the present invention are generally prepared by processesknown in the art, for example by the processes described below. In thegeneral procedures and examples provided below, the followingabbreviations are used: Et is ethyl, Me is methyl, Bn is benzyl, Ac isacetyl, AcOH is acetic acid, THF is tetrahydrofuran, DMF isdimethylformamide, rt is room temperature, Davis reagent is(1S)-(+)-(10-camphorsulfonyl)-oxaziridine, LHMDS is lithiumbis(trimethylsilyl)amide, 4-dimethylaminopyridine is DMAP,1,8-diazabicyclo[5.4.0]undec-7-ene is DBU, 1,3-dicyclohexylcarbodiimideis DCC, and trimethylsilyl iodide is TMSI.

Compounds of formula I-A, wherein B is —CH═CH—, Het is W-substitutedpyridyl, R, R¹, R³, R⁸, R⁹, R¹⁰ and R¹¹ are each hydrogen, R² is methyl,and R²² is —CO₂Et can be prepared as shown in Scheme 1:

The aldehyde 1 was converted to the dienoic acid 2 by a two steptransformation. The acid was converted to its acid chloride using oxalylchloride, which was then coupled with alcohol 3 to provide ester 4. Thealkyne was selectively reduced to the cis-alkene 5, which upon thermalcyclization gave product 6. Debenzylation, followed by double bondreduction, gave the tricyclic acid 7. The acid was converted to aldehydeIIB via its acid chloride, which was coupled with phosphonate III toprovide I-A.

In compounds of formula I-A, the ethylcarbamate group can be cleaved toprovide the amine IA-1, which can be treated with a wide range ofelectrophiles such as acid chlorides, sulfonyl chlorides, isocyanates,chloroformates etc. to provide amides, sulfonamides, ureas andcarbamates etc. as shown in Scheme 2.

The aldehyde of formula IIB can also be coupled with phosphonate 8 toprovide I-A3, which can be transformed into carbamate I-A4 as shown inScheme 3. Both I-A3 and I-A4 can be converted into diverse analogs usingmethodologies such as Suzuki coupling, Stille coupling, Buchwaldamination etc (Scheme 4).

The arylbromide I-A3 can also be converted to aniline I-A5, which can betreated with many readily accessible electrophiles such as acidchlorides, sulfonamides, isocyanates etc. to provide the correspondingderivatives I-A6 as shown in Scheme 5.

The α-position of the lactone portion can be functionalized, for examplecompounds of formula I-A wherein R³ is hydrogen can be converted to thecorresponding compounds wherein R³ is OH by treatment with Davis reagent((1S)-(+)-(10-camphorsulfonyl)-oxaziridine) and LHMDS.

Similar processes known to those skilled in the art can be used toprepare compounds comprising other optionally substituted Het groups andother “R” variables. Those skilled in the art will also recognize thatthe processes are equally applicable to preparing optically active orracemic compounds.

Compounds of formula I wherein R⁹ is hydrogen can be converted to thecorresponding compound wherein R⁹ is hydroxy by heating with anoxidizing agent such as SeO₂.

Phosphonates of formula III wherein W is aryl or R²¹-aryl can beprepared by a process similar to that described immediately below forpreparing the trifluoromethyl-phenyl-substituted compound, IIIa.

Commercially available hydroxypyridine derivative is converted to thecorresponding triflate using triflic anhydride, which is then coupledwith commercially available boronic acid in the presence of Pd(0) underSuzuki conditions. The resulting product is converted to the phosphonateby treatment with n-butyllithium followed by quenching withdiethylchlorophosphate.

Starting materials for the above processes are either commerciallyavailable, known in the art, or prepared by procedures well known in theart.

Reactive groups not involved in the above processes can be protectedduring the reactions with conventional protecting groups which can beremoved by standard procedures after the reaction. The following Table Ashows some typical protecting groups: TABLE A Group to be Pro- Group tobe Protected and tected Protecting Group —COOH —COOalkyl, —COObenzyl,—COOphenyl

—NH₂

—OH

Following are examples of preparing starting materials and compounds offormula I.

Preparation 1

Step 1:

To a solution of 5,6-dihydro-2H-pyridine-1,3-dicarboxylic acid 1-ethylester 3-methyl ester (35.4 g, 166 mmol) in CH₂Cl₂ (600 ml) at −78° C.was slowly added a solution of 1M DIBAL (365 ml, 365 mmol, 2.2 eq.) inCH₂Cl₂, and the mixture stirred for 1.5 hr. The reaction was quenched bythe addition of 1 liter of saturated aq. Rochelle's salt and the organiclayer was separated. The aqueous layer was extracted with 2×250 ml ofCH₂Cl₂ and the combined organic layer was washed with 500 ml brine,dried over MgSO₄, filtered, concentrated and the resultant crude waschromatographed with 40% EtOAc-hex to provide 17 g (55%) of alcohol asan oil.

To a solution of above alcohol (17.0 g, 92 mmol) in 150 ml of CH₂Cl₂ atrt was added NaHCO₃ (15.4 g, 183 mmol, 2 eq.) and Dess-Martin reagent(46.7 g, 110 mmol, 1.2 eq.) and the suspension was stirred for 45 min.To this was added 300 ml of Et₂O and a solution of Na₂S₂O₃.5H₂O (70 g,282 mmol, 2 eq.) and NaHCO₃ (15.4 g, 183 mmol, 2 eq.) in 600 ml H₂O. Themixture was stirred vigorously until the two layers became clear. Theorganic layer was separated and the aqueous layer was extracted with2×150 ml of Et₂O. The combined organic layer was washed with 300 ml eachof aq. Na₂S₂O₃/NaHCO₃ and brine, dried over MgSO₄, filtered andevaporated to give 15.3 g (91%) of oil. HRMS: 184.0966 (MH⁺).Step 2:

To a suspension of 60% NaH (4.35 g, 109 mmol, 1.3 eq.) in THF (300 ml)at 0° C. was added dropwise triethyl phosphonoacetate (20 ml, 109 mmol,1.3 eq) and the mixture was stirred at 0° C. for 30 min. To this wasadded a solution of the product of Step 1 (15.3 g, 83.5 mmol) and themixture was stirred for 30 min. at 0° C. The reaction was quenched bythe addition of 600 ml of aq. NH₄Cl, the THF was evaporated and theaqueous slurry was extracted with 3×200 ml of Et₂O. The combined organiclayer was washed with 200 ml of brine, dried over MgSO₄, filtered,concentrated and chromatographed with 15% EtOAc-hex to provide 19.9 g(94%) of oil. MS: 254 (MH⁺)Step 3:

To a solution of the product of Step 2 (19.9 g, 79 mmol) in 100 ml eachof CH₃OH, THF and H₂O was added KOH (13.3 g, 237 mmol, 3 eq.) and themixture was stirred at rt for 2 h. The mixture was diluted with 200 mlof H₂O, acidified with 1N HCl to ˜pH 2 and extracted with 3×200 ml ofEtOAc. The combined organic layer was washed with 200 ml each of H₂O andbrine, dried over MgSO₄, filtered and evaporated to give 17.0 g (96%) ofpale-yellow solid. HRMS: 226.1083 (MH⁺)Step 4:

To a solution of dienoic acid (17.0 g, 76 mmol) in 400 ml CH₂Cl₂ at rtwas added oxalyl chloride (13.2 ml, 151 mmol, 2 eq.) and DMF (120 μl,1.6 mmol, 2 mol %). The mixture was stirred for 1 h, concentrated andevaporated with 100 ml anhydrous toluene to provide the acid chloride.

To a solution of the above acid chloride in 200 ml CH₂Cl₂ at 0° C. wasadded DMAP (925 mg, 7.6 mmol, 0.1 eq.), a solution of the product ofStep 3 (15.4 g, 75 mmol, 1.0 eq.) in 15 ml CH₂Cl₂ followed by Et₃N (12.7ml, 91 mmol, 1.2 eq.). The mixture was stirred for 1.5 hr at 0° C., thendiluted with 600 ml of Et₂O. The solution was washed successively with200 ml H₂O, 2×200 ml 1N HCl, 200 ml aq. NaHCO₃ and 200 ml brine. It wasdried over anhydrous MgSO₄, filtered, concentrated and chromatographedwith 20% EtOAc-hex to provide 20 g (78%) of resin. HRMS: 412.1764 (MH⁺).Step 5:

A suspension of the product of Step 4 (10 g, 29 mmol), quinoline (700μl, 5.9 mmol, 0.2 eq.) and Lindlar catalyst (1.0 g, 10 wt %) in 150 mlTHF was stirred under 1 atm. H₂ for 2.5 h. Another batch of 10 g of theproduct of Step 4 was similarly reduced with Lindlar catalyst. Thebatches were combined, filtered through celite, evaporated and theresidue was re-dissolved in 600 ml EtOAc. It was washed with 3×200 ml of1N HCl and 200 ml of brine, dried over MgSO₄, filtered and evaporated togive 20 g of resin which was used immediately for the Diels-Alderreaction in Step 6. HRMS: 414.1919 (MH⁺).Step 6:

A solution of the product of Step 5 (20.0 g) in 500 ml toluene washeated in a pressure vessel at 185° C. for 6 h. It was cooled to rt,treated with DBU (1.8 ml, 12 mmol, 0.2 eq.) for 1 h, concentrated andchromatographed with 25% EtOAc-hex to provide 11.3 g (56%) of thecyclized exo product. HRMS: 414.1923 (MH⁺).Step 7:

A suspension of the product of Step 6 (11.2 g, 27 mmol), 10% Pd—C (1.2g, 10 wt %) in 200 ml EtOAc was stirred under 1 atm. H₂ until thereaction was complete. It was filtered through celite, concentrated andre-dissolved in 200 ml of CH₃OH. To this was added 900 mg of PtO₂ andthe suspension was shaken under 50 atm. of H₂ in a parr vessel. Themixture was filtered through celite and concentrated to provide 8.5 g ofresin. HRMS: 326.100 (MH⁺).

Step 8:

To a solution of the product of Step 7 (415 mg, 1.28 mmol) in 10 mlCH₂Cl₂ at rt was added oxalyl chloride (225 μl, 2.58 mmol, 2 eq.)followed by 1 drop of DMF. The solution was stirred at rt for 1 h, atwhich time there was no evolution of gas. It was concentrated andazeotroped with anhydrous toluene to give the acid chloride. The acidchloride was dissolved in 6 ml of anhydrous toluene, cooled to 0° C. andPd(PPh₃)₄ (74 mg, 0.064 mmol, 5 mol %) was added, followed by Bu₃SnH(520 μl, 1.93 mmol, 1.5 eq.). The mixture was stirred at 0° C. for 3 hr,concentrated and chromatographed with 50% EtOAc-hex to provide 360 mg(91%) of the title compound as a resin. MS: 310.1 (MH⁺).

Preparation 2

3-Formyl-5,6-dihydro-2H-pyran was converted to the tricyclic aldehydeusing similar procedure described above for the corresponding amineanalogs.

Preparation 3

To a solution of the phosphonate (3.49 g, 11.3 mmol, 2 eq.) in THF (50ml) at 0° C. was added a 1M solution of LHMDS in THF (11.3 ml, 11.3mmol, 2 eq.). After stirring for 10 min., Ti(O^(i)Pr)₄ (3.4 ml, 11.3mmol, 2 eq.) was added, followed by a solution of Preparation 1 (1.75 g,5.7 mmol, 1 eq.) in THF (10 ml), and the mixture was stirred for 1 hunder N₂. The reaction mixture was poured into 5% aqueous tartaric acidsolution (100 ml) and extracted with EtOAc (3×100 ml). The combinedorganic layers were washed with brine (150 ml), dried with MgSO₄,filtered and evaporated to dryness. Purification by silica gelchromatography eluting with 5% CH₃OH—CH₂Cl₂ yielded 1.80 g (70%) of thetitle compound as a pale yellow foam. ¹H NMR (400 MHz, CDCl₃): 8.59 (d,J=4.8 Hz, 1H), 7.76 (dd, J=3 Hz, 8.4 Hz, 1H), 7.06 (d, J=8.4 Hz, 1H),6.56 (dd, J=9.6 Hz, 15.2 Hz, 1H), 6.45 (d, J=15.2 Hz, 1H), 4.73 (m, 1H),4.35-4.05 (m, 2H), 4.12 (q, J=6.8 Hz, 2H), 2.73-2.69 (m, 2H), 2.47-2.35(m, 3H), 1.96 (q, 6.0 Hz, 1H), 1.74 (d, J=12.8 Hz, 1H), 1.41 (d, J=6.0Hz, 3H), 1.35-1.18 (m, 7H), 1.10-0.98 (m, 1H).

Preparation 4

To a solution of Preparation 3 (0.270 g, 0.58 mmol) in CH₂Cl₂ (15 ml)was added TMSI (624 μl, 4.4 mmol, 7.5 eq.), and the mixture was heatedto reflux. After 6 h, the mixture was poured onto aqueous NaHCO₃ (30 ml)and extracted with CH₂Cl₂ (3×15 ml). The combined organic layers werewashed with brine, dried with MgSO₄, filtered and evaporated to drynessresulting in 209 mg of amine (92%).

To the above product in CH₂Cl₂ (15 ml) at 0° C. was added Et₃N (97 μl,0.69 mmol, 1.3 eq.) and chloroformic acid 2-methoxyethyl ester (68 □l,5.9 mmol, 1.1 eq.); the mixture was allowed to slowly warm to rt whilestirring under N₂. After 1 h, the mixture was poured onto water (30 ml)and extracted with CH₂Cl₂ (3×15 ml). The combined organic layers werewashed with brine (30 ml), dried with MgSO₄, filtered and evaporated todryness. Purification by silica gel chromatography, eluting with 3%CH₃OH—CH₂Cl₂, yielded 183 mg of the title compound as a white solid(69%). ¹H NMR (400 MHz, CDCl₃): 8.59 (d, J=2.4 Hz, 1H), 7.76 (dd, J=2.4,8.2 Hz, 1H), 7.06 (d, J=8.3 Hz, 1H) 6.56 (dd, J=9.6, 15.4 Hz, 1H), 6.45(d, J=15.4 Hz, 1H), 4.72 (m, 1H), 4.1-4.28 (m, 4H), 3.59 (t, J=4.49 Hz,2H), 3.38 (s, 3H), 2,75-2.68 (m, 2H), 2.32-2.51 (m, 3H), 1.96 (dd,J=6.3, 12.8 Hz, 1H), 1.73 (d, J=12.5 Hz, 1H), 1.41 (d, J=5.95 Hz, 3H),1.37-1.00 (m, 4H).

Preparation 5

Step 1:

The thiopyran enal was prepared according to the procedure of McGinnisand Robinson, J. Chem. Soc., 404 (1941), 407.Step 2:

To a suspension of 60% NaH (6.3 g, 158 mmol, 1.3 eq.) in THF (200 ml) at0° C. was added methyl diethylphosphonoacetate (29 ml, 158 mmol, 1.3eq.) and the mixture was stirred at 0° C. for 30 min. The solution wasthen transferred to a solution of the product of Step 1 (15.6 g, 122mmol) in THF (100 ml) and stirred at 0° C. for 1 h. The reaction wasquenched by the addition of aq. NH₄Cl (500 ml) and the THF wasevaporated. The aqueous phase was extracted with Et₂O (3×200 ml) and thecombined organic layer was washed with H₂O and brine (200 ml each). Thesolution was dried over MgSO₄, concentrated and the resultant residuewas chromatographed with 5% EtOAc-hexane to provide 13.0 g (58%) of oil.¹H NMR (400 MHz, CDCl₃) 7.26 (d, J=15.9 Hz, 1H), 6.26 (t, J=4.4 Hz, 1H),5.78 (dd, J=15.9, 0.6 Hz, 1H), 3.75 (s, 3H), 3.25-3.23 (m, 2H), 2.71 (t,J=5.8 Hz, 2H), 2.57-2.53 (m, 2H).Step 3:

To a solution of the product of Step 2 (13.0 g, 70.6 mmol) in THF andMeOH (50 ml each) was added a solution of KOH (11.9 g, 212 mmol, 3.0eq.) in H₂O (50 ml). The mixture was stirred at rt for 1 h, diluted withH₂O (100 ml) and acidified with 1N HCl. The aqueous phase was extractedwith EtOAc (3×200 ml) and the combined organic layer was washed with H₂Oand brine (300 ml each). The solution was dried over MgSO₄, filtered andevaporated to give 11.66 g (97%) of pale-yellow solid. ¹H NMR (400 MHz,CDCl₃) 7.34 (d, J=15.6 Hz, 1H), 6.32 (t, J=4.4 Hz, 1H), 5.78 (d, J=15.6Hz, 1H), 3.26 (d, J=1.6 Hz, 2H), 2.72 (t, J=5.8 Hz, 2H), 2.59-2.55 (m,2H).Step 4:

To a solution of 4 (5.2 g) in EtOAc (120 ml) was added Lindlar catalyst(520 mg) and the suspension was stirred under 1 atm. H₂. Another portionof catalyst (500 mg) was added after 45 min. and the mixture stirred forfurther 30 min. The mixture was filtered through a celite pad andevaporated to provide 5.2 g (99%) of the desired alkene. ¹H NMR (400MHz, CDCl₃) 7.38-7.26 (m, 5H), 6.32 (dd, J=11.9, 6.6 Hz, 1H), 5.86 (d,J=12.0 Hz, 1H), 5.18 (s, 2H), 5.12-5.07 (m, 1H), 3.20 (brs, 1H), 1.34(d, J=6.6 Hz, 3H).Step 5:

To a solution of the product of Step 3 (2.45 g, 14.39 mmol) in CH₂Cl₂(60 ml) at 0° C. was added DCC (3.27 g, 15.85 mmol, 1.1 eq.) followed byDMAP (352 mg, 2.88 mmol, 0.2 eq.) and the mixture was stirred at 0° C.for 30 min. To this was added a solution of 3.27 g (15.85 mmol, 1.1 eq.)of the alcohol of Step 4 in 10 ml of CH₂Cl₂ and the mixture was stirredat 0° C. for 5 hr and at rt for 1 hr. The solution was diluted with 350ml of Et₂O and washed with 2×200 ml of aq. citric acid, 200 ml of aq.NaHCO₃ and 200 ml of brine. The solution was dried over MgSO₄, filtered,concentrated and the resultant residue was chromatographed with 6%EtOAc-hex to provide 2.1 g (41%) of resin. ¹H NMR (400 MHz, CDCl₃)7.38-7.32 (m, 5H), 7.45 (d, J=16.0 Hz, 1H), 6.38-6.34 (m, 1H), 6.26 (t,J=4.6 Hz, 1H), 6.21 (d, J=11.6 Hz, 1H), 6.19 (d, J=11.2 Hz, 1H), 5.85(dd, J=11.6, 1.2 Hz, 1H), 5.76 (d, J=16.0 Hz, 1H), 5.18 (d, J=1.2 Hz,2H), 3.24 (d, J=2.0 Hz, 2H), 2.71 (t, 2H, J=5.6 Hz, 2H), 2.56-2.52 (m,2H), 1.41 (d, J=6.4 Hz, 3H)Step 6:

A solution of the product of Step 5 (2.1 g, 5.85 mmol) in m-xylene (50ml) was heated at 200° C. for 6 h in sealed tube. The solution wascooled to rt and stirred with DBU (178 □l, 1.19 mmol, 0.2 eq.) for 1 h,concentrated and chromatographed with 15% EtOAc-hexane to provide 1.44 g(69%) of the desired exo product. ¹H NMR (400 MHz, CDCl₃) 7.39-7.35 (m,5H), 5.46 (br s, 1H), 5.16 (ABq, J=21.6, 12.0 Hz, 2H), 4.42 (dq, J=9.2,6.0 Hz, 1H), 3.36-3.33 (m 2H), 3.08 (dd, J=14.4, 2.4 Hz, 1H), 2.85 (ddd,J=13.9, 12.4, 2.5 Hz, 1H), 2.72-2.57 (m, 4H), 2.27-2.21 (m, 1H),1.47-1.25 (m, 1H), 1.12 (d, J=6.4 Hz, 3H)Step 7:

To a solution of the product of Step 6 (750 mg, 2.09 mmol) in CH₂Cl₂ (10ml) at −78° C. was added BBr₃ in CH₂Cl₂ (4.2 ml of 1M solution). Thesolution was stirred at −78° C. for 30 min. and at 0° C. for 30 min,then poured into aq. K₂CO₃ (100 ml). The aqueous phase washed with Et₂O(2×50 ml) and the organic layer was back extracted with aq. K₂CO₃ (50ml). The combined aqueous phase was acidified with 1N HCl and extractedwith EtOAc (3×50 ml). The EtOAc layer was washed with brine (50 ml),dried over MgSO₄, filtered and evaporated to provide 500 mg (89%) ofacid. ¹H NMR (400 MHz, CDCl₃) 5.50 (br s, 1H), 4.47 (dq, J=9.6, 6.0 Hz,1H), 3.43-3.39 (m, 1H), 3.36 (d, J=15.6 Hz, 1H), 3.10 (dd, J=14.0, 2.4Hz, 1H), 2.91-2.84 (m, 1H), 2.82-2.77 (m, 1H), 2.70 (dd, J=10.6, 4.2 Hz,1H), 2.69-2.63 (m, 1H), 2.57-2.52 (m, 1H), 2.34-2.29 (m, 1H), 1.53-1.42(m, 1H), 1.34 (d, J=6.0 Hz, 3H).Step 8:

To a solution of the product of Step 7 (500 mg, 1.86 mmol) in MeOH (30ml) was added AcOH (3 ml) and PtO₂ (250 mg) and the suspension wasshaken under 40 Psi H₂ in a Parr vessel for 1.5 days. The catalyst wasfiltered off with a celite pad, the solution was concentrated and theresultant residue was dissolved in AcOH-MeOH—CH₂Cl₂ mixture (0.5:2:97.5v/v/v/) and filtered through a short SiO₂ column to provide 400 mg (79%)of the reduced product as a resin which solidified on standing. ¹H NMR(400 MHz, CDCl₃) 4.68 (dq, J=9.4, 5.9 Hz, 1H), 2.76-2.69 (m, 2H),2.60-2.55 (m, 3H), 2.49 (d, J=11.6 Hz, 1H), 2.10 (brs, 1H), 1.93 (ddd,J=13.5, 6.0, 2.7 Hz, 1H), 1.60-1.48 (m, 2H), 1.45-1.19 (m, 3H), 1.33 (d,J=5.6 Hz, 3H).

Step 9:

To a solution of the product of Step 8 (97 mg, 0.36 mmol) in CH₂Cl₂ (4ml) was added oxalyl chloride (94 μl) followed by 1 drop of DMF. Thesolution was stirred for 1 h at rt and concentrated to provide the crudeacid chloride which was dissolved in toluene (3 ml) and cooled to 0° C.Pd(PPh₃)₄ (42 mg, 0.04 mmol, 0.1 eq.) was added, followed by Bu₃SnH (94μl). The mixture was stirred at 0° C. for 3 h, concentrated andchromatographed with 25% EtOAc-hexane to provide 73 mg (80%) of aldehydeas white solid. ¹H NMR (400 MHz, CDCl₃) 9.75 (d, J=2.8 Hz, 1H), 4.62(dq, J=9.7, 6.0 Hz, 1H), 2.8-2.70 (m, 2H), 2.65-2.55 (m, 3H), 2.50 (d,J=7.2 Hz), 2.10 (ddd, J=13.2, 6.4, 3.0 Hz, 1H), 1.94 (ddd, J=13.6, 6.0,3.0, 1H), 1.69 (dq, J=10.9 Hz, 3.00 Hz, 1H), 1.58-1.48 (m, 1H),1.42-1.20 (m, 3H), 1.33 (d, J=6.4 Hz, 3H).

Preparation 6

Step 1:

δ-Valerolactam was dissolved in THF (250 ml) and cooled to −78° C.n-BuLi (28.44 ml, 1.1 eq, 2.5 M solution in hexanes) was added dropwise.The mixture was stirred for 30 min, then ethyl chloroformate (6.49 ml,1.05 eq) was added and the mixture allowed to warm to rt. Water wasadded and the organic layer extracted with EtOAc. The combined organiclayers were dried and concentrated to give 11.57 g of oil. ¹H NMR (400MHz, CDCl₃) 4.29 (2H, q, J=7.2 Hz), 3.71 (2H, br t, J=5.6 Hz), 2.50 (2H,br t, J=6.8 Hz), 1.83 (4H, br s), 1.33 (3H, t, J=7.2 Hz).Step 2:

The product of step 1 was dissolved in THF (250 ml) and the solutioncooled to −78° C. LHMDS (65 ml, 1 eq, 1 M solution in THF) was addeddropwise and the resulting mixture stirred for 30 min. A solution of2-[N,N-bis(trifluoromethylsulfonyl)-amino]-5-chloropyridine in THF (73ml) was added dropwise. The resulting mixture was stirred for 10 min andallowed to warm to rt. Water was added and the organic layer extractedwith EtOAc. The combined organic layers were dried and concentrated.Chromatography (5-10% EtOAc in Hexane) gave 12.0 g of oil.

¹H NMR (400 MHz, CDCl₃) 5.32 (1H, t, J=3.6 Hz), 4.24 (2H, q, J=7.2 Hz),3.66 (2H, m), 2.27 (2H, m), 1.78 (2H, m), 1.30 (3H, J=7.2 Hz).Step 3:

Borane dimethylsulfide complex (5.82 ml, 1.05 eq) was dissolved in THFand cooled to 0° C. (1R)-(+)-α-pinene (22.56 ml, 2.32 eq) was addeddropwise, the mixture was stirred at 0° C. for 1 h and at rt for 2 h.The mixture was cooled to −35° C. and ethyl propiolate (6.2 ml, 1 eq)was added dropwise; the mixture was stirred at −35° C. for 45 min and rtfor 3 h. Acetaldehyde (48 ml) was added and the mixture heated at 40-41°C. overnight. The volatile organic components were carefully removedunder reduced pressure to give 29 g of a mixture of the product andα-pinene (1:2.3 by NMR). ¹H NMR (400 MHz, CDCl₃) characteristic peaksfor the product include, 6.95 (1H, d, J=18.0 Hz), 6.48 (1H, d, J=18.0Hz), 4.12 (2H, q, J=7.2 Hz), 3.60 (4H, q, J=7.2 Hz).Step 4:

Pd(OAc)₂ (592 mg, 10%) and 2-(di-t-butylphosphino)biphenyl (1.57 g, 20%)were dissolved in THF (100 ml). The mixture was stirred for 10 min underN₂, then a mixture of the product from step 2 (8 g) and the product fromstep 3 (20 g, 1.5 eq) in THF (32 ml) were added. KF (4.6 g) was thenadded and the mixture heated at 55° C. overnight. The mixture wasallowed to cool to rt and diluted with EtOAc. The mixture was washedwith NaHCO₃(sat), NH₄Cl(sat), water, and finally dried over MgSO₄.Removal of solvents under reduced pressure followed by columnchromatography (10% EtOAc in hexane) gave 6 g (89%) of a colorless oil.¹H NMR (400 MHz, CDCl₃) 7.21 (1H, d, J=15.6 Hz), 5.88 (1H, d, J=15.6Hz), 5.69 (1H, t, J=4.0 Hz), 4.15 (4H, m), 3.59 (2H, m), 2.26 (2H, m),1.82 (2H, m), 1.25 (6H, m).

Step 5:

The product from step 4 was dissolved in a 1:1 mixture of MeOH and THF(66 ml). A solution of 1N NaOH (52 ml) was added and the mixture stirredfor 2.5 h until no starting material remained.

The mixture was acidified to pH1 with 2 N HCl and extracted with EtOAc.The extracts were washed with NH₄Cl (sat), dried, and concentrated underreduced pressure to give 5 g of a solid. ¹H NMR (400 MHz, CDCl₃) 7.30(1H, d, J=15.2 Hz), 5.87 (1H, d, J=15.2 Hz), 5.73 (1H, m), 4.14 (2H, m),3.60 (2H, m), 2.70 (2H, m), 1.82 (2H, m), 1.23 (3H, m).

EXAMPLE 1

To a solution of phosphonate (156 mg, 0.42 mmol, 2.0 eq.) in THF (1 ml)at 0° C. was added a 2.5 M solution of BuLi in hexanes (170 μl, 0.42mmol, 2.0 eq.) and the mixture was stirred for 30 min. To this was addeda solution of Preparation 5 (53 m, 0.21 mmol) in THF (1.5 ml) and themixture was stirred at 0° C. for 1 h. The reaction was quenched by theaddition of aq. NH₄Cl (20 ml), the THF was evaporated and the aqueousphase was extracted with CH₂Cl₂ (3×10 ml). The combined organic layerwas washed with aq. NaHCO₃ (15 ml) and brine (15 ml), dried over MgSO₄,filtered, concentrated and chromatographed with 40% EtOAc-hex to provide90 mg (91%) of resin. HRMS: 474.1721.

The thiopyran compound of Example 1 can be converted to thecorresponding sulfoxide (1A) and sulfone (1B) by the followingprocedure:

To a solution of Example 1A (70 mg, 0.15 mmol) in AcOH (2 ml) was addedCH₃SO₃H (50 μl, 5 eq.) and NaBO₃.4H₂O (30 mg, 0.19 mmol, 1.3 eq.), andthe mixture was stirred overnight at rt. The acetic acid was evaporatedand the resultant residue was taken in aq. NaHCO₃—Na₂SO₃ mixture (25 ml)and extracted with CH₂Cl₂ (3×15 ml). The combined organic layer waswashed with brine (20 ml), dried over MgSO₄, filtered, concentrated andpurified by preparative thin layer chromatography to provide 11 mg ofsulfoxide isomer 1, 4 mg of sulfoxide isomer 2, and 36 mg of sulfone.

Sulfoxide isomer 1: HRMS: 490.1661 (MH₊);

Sulfoxide isomer 2: ¹H NMR (400 MHz, CDCl₃): 8.80 (d, J=2.4 Hz, 1H),7.87 (dd, J=8.0, 2.0 Hz, 1H), 7.81 (s, 1H), 7.76 (d, J=7.6 Hz, 1H), 7.67(d, J=7.6 Hz, 1H), 7.61 (t, J=7.8 Hz, 1H), 7.27 (d, J=9.6 Hz, 1H),6.67-6.55 (m, 2H), 4.78-4.71 (m, 1H), 3.44-3.40 (m, 1H), 3.35 (dt,J=12.1, 2.8 Hz, 1H), 2.78-2.71 (m, 1H), 2.64-2.57 (m, 1H), 2.52-2.36 (m,3H), 2.26-2.21 (m, 1H), 2.04 (ddd, J=13.5, 6.5, 2.7 Hz, 1H), 1.45 (d,J=6.0 Hz, 3H), 1.60-1.25 (m, 6H)

Sulfone: HRMS: 506.1612 (MH⁺).

EXAMPLE 2

General Procedure:

To a solution of phosphonate (2 eq) in THF at 0° C. is added 2.5M BuLiin hexanes (2.0 eq.). After stirring for about 2 h, Ti(O^(i)Pr)₄ (2.0eq) is added, followed by a solution of aldehyde in THF (1.0 eq.). Themixture is stirred at rt for 30 min, diluted with aq. sodium potassiumtartrate and extracted with EtOAc. The combined organic layer is washedwith brine, dried over MgSO₄, filtered, concentrated and purified bycolumn chromatography to provide the product.

Compounds of the following formula were prepared by this generalprocedure:

wherein W and Z are as defined in the table: Ex. W Z Analytical DataHRMS (MH⁺) 2A

—N(CO₂Et)— 529.2313 2B

—O— 458.1941 2C

—O— 408.1982 2D

—N(CO₂Et)— 479.2348 2E

—N(CO₂Et)— 479.2339 2F

—O— 426.1881 2G

—O— 424.1686 2H

—N(CO₂Et)— 497.2246 2I

—O— 424.1684 2J

—O— 458.1299

EXAMPLE 3

To a solution of Example 2D (380 mg, 0.79 mmol) in THF (7 ml) at −78° C.was added 1M solution of LHMDS in THF (0.95 ml, 0.95 mmol, 1.2 eq.); themixture was stirred for 30 min at −78° C., 30 min at 0° C., then cooledback to −78° C. To this was added a solution of(1S)-(+)-(10-camphorsulfonyl)oxaziridine (275 mg, 1.1 mmol, 1.5 eq.) inTHF (2 ml). The solution was stirred overnight while allowing to warm upto rt. It was diluted with aq. NH₄Cl (100 ml), the THF was evaporatedand the aqueous phase extracted with EtOAc (3×30 ml). The combinedorganic layer was washed with brine (30 ml), dried over MgSO₄, filtered,concentrated and chromatographed with 2% CH₃OH—CH₂Cl₂ to provide 94 mgof resin. HRMS: 495.2291 (MH⁺)

EXAMPLE 4

General Procedure:

A solution of carbamate and trimethylsilyl iodide (5 eq.) was refluxedfor about 5 hr then diluted with aq. NaHCO₃. The aqueous layer wasextrated with CH₂Cl₂ and the combined organic layers was washed withbrine, dried over MgSO₄, filtered and concentrated to give the amine.

A solution of the amine from above in CH₂Cl₂ was treated with Et₃N (5eq.) and acid chloride (3 eq) and the reaction was followed by thinlayer chromatography. After the reaction was completed, it was subjectedto standard aqueous work-up and the crude product was purified bypreparative thin layer chromatography or column chromatography to affordthe amide.

The amine can similarly be treated with many electrophiles such assulfonylchlorides, isocyanates, chloroformates and aldehydes etc. toprovide the appropriate derivatives. Compounds of the following formulawere prepared by this route:

wherein W and R²² are as defined in the table: Analytical Data HRMS Ex.W R²² (MH⁺) 4A

499.2209 4B

525.2372 4C

535.1873 4D

549.2031 4E

563.2191 4F

528.2470 4G

542.2631 4H

542.2610 4I

556.2786 4J

557.2625 4K

H 457.2093 4L

513.2347 4M

527.2523 4N

591.2464 4O

591.2021 4P

561.2375 4Q

539.2530 4R

527.2517 4S

475.2406 4T

478.2515 4U

485.1901 4V

475.2411 4W

478.2520 4X

485.1906 4Y

513.2227 4Z

561.2214 4AA

450.2187 4AB

525.2554 4AC

539.2716 4AD

493.2297 4AE

496.2403 4AF

503.1819 4AG

471.2255

EXAMPLE 5

General Procedure:

A solution of a product of Preparation 3 or 4 and W-B(OH)₂, wherein W isoptionally substituted phenyl or heteroaryl, K₂CO₃ (4 eq.) and Pd(PPh₃)₄(5 to 10 mol %) in PhMe-EtOH—H₂O (4:2:1 v/v/v) was heated at 100° C.until the reaction was complete. The reaction mixture was diluted withH₂O, extracted with EtOAc, the organic layer was washed with brine,dried over MgSO₄, filtered, concentrated and purified by chromatographyto provide the desired compounds. The compounds can be furtherderivatized.

Using this method, compounds of the following formula were prepared

wherein R²³ and W are as defined in the table: Analytical Data Ex. W R²³HRMS (MH⁺) 5A

OEt 486.2399 5B

OEt 467.1998 5C

OEt 518.2655 5D

OEt 546.2964 5E

OEt 451.2239 5F

OEt 462.2390 5G

OEt 461.2438 5H

OEt 475.2604 51

OCH₂CH₂OMe 491.2542 5J

OCH₂CH₂OMe 509.2448

EXAMPLE 6

To a solution of Preparation 3 (100 mg, 0.22 mmol) in toluene (5 ml) wasadded Pd(OAc)₂ (5 mg, 0.022 mmol, 0.1 eq.),(S)-(−)-2,2′-bis(diphenylphoshphino)-1,1′-binaphthyl (13 mg, 0.022 mmol,0.1 eq.) and 2-tributylstannyl pyridine (119 mg, 0.32 mmol, 1.5 eq.).The mixture was bubbled with N₂ for 5 min., then heated to 100° C. in apressure tube. After 16 h, the mixture was poured onto aqueous NH₄Cl (15ml), and extracted with EtOAc (3×1 5 ml). The combined organic layerswere washed with brine, dried with MgSO₄, filtered and evaporated todryness. Purification by silica gel chromatography, eluting with 2%CH₃OH—CH₂Cl₂, followed by silica gel chromatography eluting with 60%EtOAc-hex, yielded 30 mg (30%) of product. HRMS: 462.2401 (MH⁺)

Using a similar procedure, the following compound 6A was prepared:

EXAMPLE 6A

MS: 468 (MH⁺)

EXAMPLE 7

To a solution of Preparation 3 (100 mg, 0.22 mmol) in dry toluene (5 ml)was added pyrrolidine (36 μl, 0.43 mmol, 2 eq.), potassium phosphate(137 mg, 0.65 mmol, 5 eq.), Pd(OAc)₂ (3 mg, 0.014 mmol, 0.065 eq.), and2-(dicyclohexyl-phosphino)biphenyl (10 mg, 0.028 mmol, 0.13 eq.). Themixture was bubbled with N₂ for 5 min., then heated to 100° C. in apressure tube. After 16 h, the mixture was poured onto water (15 ml) andextracted with EtOAc (3×1 5 ml). The combined organic layers were washedwith brine (15 ml), dried with MgSO₄, filtered and evaporated todryness. Purification by preparative thin layer chromatography, elutingwith 5% CH₃OH—CH₂Cl₂, yielded 10 mg of solid HRMS: 454.2696 (MH⁺)

Using a similar procedure, the following compound was prepared:

EXAMPLE 7A

HRMS: 440.2558 (MH⁺)

EXAMPLE 8

To a solution of Preparation 3 (1.0 g, 2.18 mmol) in ethylene glycoldimethyl ether (25 ml) was added benzophenone imine (550 μl, 3.27 mmol,1.5 eq.), potassium phosphate (1.51 g, 6.6 mmol, 3 eq.),tris(dibenzylideneacetone)dipalladium(0) (200 mg, 0.22 mmol, 0.1 eq.)and 2-(dicyclohexylphosphino)biphenyl (153 mg, 0.44 mmol, 0.2 eq.). Themixture was bubbled with N₂ for 5 min., then heated to 100° C. in apressure tube for 4 h. The mixture was then filtered through celite andevaporated to dryness. To this residue in CH₂Cl₂ (25 ml) was addedconcentrated aqueous HCl (545 μL, 6.6 mmol, 3 eq.) and the mixture wasstirred at rt. After 16 h, the mixture was diluted with CH₂Cl₂ (25 ml),poured onto aqueous 1N NaOH (50 ml) and extracted with CH₂Cl₂ (3×50 ml).The combined organic layers were washed with brine, dried with MgSO₄,filtered and evaporated to dryness. Purification by silica gelchromatography, eluting with 2% CH₃OH—CH₂Cl₂ yielded 550 mg (63%) of thetitle compound. MS: 400 (MH⁺)

The compound of Example 8 was treated with electrophiles such as acidchlorides, sulfonyl chlorides, isocyanates etc. to provide the followingcompounds.

wherein —NHC(O)R²⁶ is as defined in the table: Ex. —NHR⁴ Analytical DataHRMS (MH⁺) 8A

468.2505 8B

510.2058 8C

518.2621 8D

524.2209 8E

504.2498 8F

478.2019 8G

492.2160 8H

471.2600 8I

506.2318

EXAMPLE 9

Using the product of Preparation 6 and the general procedures ofPreparation 1, Preparation 3 and Example 5, compounds of the followingstructure were prepared

wherein W is as defined in the following table: Ex W Analytical DataHRMS (MH⁺) 9A

479.2350 9B

479.2350 9C

486.2399

The present invention also relates to a pharmaceutical compositioncomprising at least one compound of formula I of this invention and apharmaceutically acceptable carrier. Preferably, one or two compounds offormula I are present in the composition, more preferably one compoundof formula I. The compounds of formula I can be administered in anyconventional oral dosage form such as capsules, tablets, powders,cachets, suspensions or solutions. The formulations and pharmaceuticalcompositions can be prepared using conventional pharmaceuticallyacceptable excipients and additives and conventional techniques. Suchpharmaceutically acceptable excipients and additives include non-toxiccompatible fillers, binders, disintegrants, buffers, preservatives,anti-oxidants, lubricants, flavorings, thickeners, coloring agents,emulsifiers and the like.

The daily dose of a compound of formula I for treatment of a disease orcondition cited above is about 0.001 to about 100 mg/kg of body weightper day, preferably about 0.001 to about 10 mg/kg. For an average bodyweight of 70 kg, the dosage level is therefore from about 0.1 to about700 mg of drug per day, given in a single dose or 2-4 divided doses. Theexact dose, however, is determined by the attending clinician and isdependent on the potency of the compound administered, the age, weight,condition and response of the patient.

The following formulations exemplify some of the dosage forms of thisinvention. In each, the term “active compound” designates a compound offormula I.

EXAMPLE A Tablets

No. Ingredient mg/tablet mg/tablet 1 Active Compound 100 500 2 LactoseUSP 122 113 3 Corn Starch, Food Grade, as a 10% 30 40 paste in PurifiedWater 4 Corn Starch, Food Grade 45 40 5 Magnesium Stearate 3 7 Total 300700Method of Manufacture

Mix Item Nos. 1 and 2 in suitable mixer for 10-15 minutes. Granulate themixture with Item No. 3. Mill the damp granules through a coarse screen(e.g., ¼″, 0.63 cm) if necessary. Dry the damp granules. Screen thedried granules if necessary and mix with Item No. 4 and mix for 10-15minutes. Add Item No. 5 and mix for 1-3 minutes. Compress the mixture toappropriate size and weight on a suitable tablet machine.

EXAMPLE B Capsules

No. Ingredient mg/tablet mg/tablet 1 Active Compound 100 500 2 LactoseUSP 106 123 3 Corn Starch, Food Grade 40 70 4 Magnesium Stearate NF 4 7Total 250 700Method of Manufacture

Mix Item Nos. 1, 2 and 3 in a suitable blender for 10-15 minutes. AddItem No. 4 and mix for 1-3 minutes. Fill the mixture into suitabletwo-piece hard gelatin capsules on a suitable encapsulating machine.

The activity of the compounds of formula I can be determined by thefollowing procedures.

In Vitro Testing Procedure for Thrombin Receptor Antagonists:

Preparation of [³H]haTRAP

A(pF-F)R(ChA)(hR)(I₂-Y)-NH₂ (1.03 mg) and 10% Pd/C (5.07 mg) weresuspended in DMF (250 μl) and diisopropylethylamine (10 μl). The vesselwas attached to the tritium line, frozen in liquid nitrogen andevacuated. Tritium gas (342 mCi) was then added to the flask, which wasstirred at room temperature for 2 hours. At the completion of thereaction, the excess tritium was removed and the reacted peptidesolution was diluted with DMF (0.5 ml) and filtered to remove thecatalyst. The collected DMF solution of the crude peptide was dilutedwith water and freeze dried to remove the labile tritium. The solidpeptide was redissolved in water and the freeze drying process repeated.The tritiated peptide ([³H]haTRAP) was dissolved in 0.5 ml of 0.1%aqueous TFA and purified by HPLC using the following conditions: column,Vydac C18, 25 cm×9.4 mm I.D.; mobile phase, (A) 0.1% TFA in water, (B)0.1% TFA in CH₃CN; gradient, (A/B) from 100/0 to 40/60 over 30 min; flowrate, 5 ml/min; detection, UV at 215 nm. The radiochemical purity of[³H]haTRAP was 99% as analyzed by HPLC. A batch of 14.9 mCi at aspecific activity of 18.4 Ci/mmol was obtained.

Preparation of Platelet Membranes

Platelet membranes were prepared using a modification of the method ofNatarajan et al (Natarajan et al, Int. J. Peptide Protein Res.45:145-151 (1995)) from 20 units of platelet concentrates obtained fromthe North Jersey Blood Center (East Orange, N.J.) within 48 hours ofcollection. All steps were carried out at 4° C. under approved biohazardsafety conditions. Platelets were centrifuged at 100×g for 20 minutes at4° C. to remove red cells. The supernatants were decanted andcentrifuged at 3000×g for 15 minutes to pellet platelets. Platelets wereresuspended in 10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA, to atotal volume of 200 ml and centrifuged at 4400×g for 10 minutes. Thisstep was repeated two additional times. Platelets were resuspended in 5mM Tris-HCl, pH 7.5, 5 mM EDTA to a final volume of approximately 30 mland were homogenized with 20 strokes in a Dounce homogenizer. Membraneswere pelleted at 41,000×g, resuspended in 40-50 ml 20 mM Tris-HCl, pH7.5, 1 mM EDTA, 0.1 mM dithiothreitol, and 10 ml aliquots were frozen inliquid N₂ and stored at −80° C. To complete membrane preparation,aliquots were thawed, pooled, and homogenized with 5 strokes of a Douncehomogenizer. Membranes were pelleted and washed 3 times in 10 mMtriethanolamine-HCl, pH 7.4, 5 mM EDTA, and resuspended in 20-25 ml 50mM Tris-HCl, pH 7.5, 10 mM MgCl₂, 1 mM EGTA, and 1% DMSO. Aliquots ofmembranes were frozen in liquid N₂ and stored at −80° C. Membranes werestable for at least 3 months. 20 units of platelet concentratestypically yielded 250 mg of membrane protein. Protein concentration wasdetermined by a Lowry assay (Lowry et al, J. Biol. Chem., 193:265-275(1951)). High Throughput Thrombin Receptor Radioligand Binding Assay

Thrombin receptor antagonists were screened using a modification of thethrombin receptor radioligand binding assay of Ahn et al. (Ahn et al,Mol. Pharmacol. 51:350-356 (1997)). The assay was performed in 96 wellNunc plates (Cat. No. 269620) at a final assay volume of 200 μl.Platelet membranes and [³H]haTRAP were diluted to 0.4 mg/ml and 22.2 nM,respectively, in binding buffer (50 mM Tris-HCl, pH 7.5, 10 mM MgCl₂, 1mM EGTA, 0.1% BSA). Stock solutions (10 mM in 100% DMSO) of testcompounds were further diluted in 100% DMSO. Unless otherwise indicated,10 μl of diluted compound solutions and 90 μl of radioligand (a finalconcentration of 10 nM in 5% DMSO) were added to each well, and thereaction was started by the addition of 100 μl of membranes (40 μgprotein/well). The binding was not significantly inhibited by 5% DMSO.Compounds were tested at three concentrations (0.1, 1 and 10 μM). Theplates were covered and vortex-mixed gently on a Lab-Line Titer PlateShaker for 1 hour at room temperature. Packard UniFilter GF/C filterplates were soaked for at least 1 hour in 0.1% polyethyleneimine. Theincubated membranes were harvested using a Packard FilterMate UniversalHarvester and were rapidly washed four times with 300 μl ice cold 50 mMTris-HCl, pH 7.5, 10 mM MgCl₂, 1 mM EGTA. MicroScint 20 scintillationcocktail (25 μl) was added to each well, and the plates were counted ina Packard TopCount Microplate Scintillation Counter. The specificbinding was defined as the total binding minus the nonspecific bindingobserved in the presence of excess (50 μM) unlabeled haTRAP. The %inhibition by a compound of [³H]haTRAP binding to thrombin receptors wascalculated from the following relationship:${\%\quad{Inhibition}} = {\frac{\begin{matrix}{{{Total}\quad{binding}} - {{Binding}\quad{in}\quad{the}\quad{presence}}} \\{{of}\quad a\quad{test}\quad{compound}}\end{matrix}}{{{Total}\quad{binding}} - {{Nonspecific}\quad{binding}}} \times 100}$Materials

A(pF-F)R(ChA)(hR)Y—NH₂ and A(pF-F)R(ChA)(hR)(I₂-Y)—NH₂, were customsynthesized by AnaSpec Inc. (San Jose, Calif.). The purity of thesepeptides was >95%. Tritium gas (97%) was purchased from EG&G Mound,Miamisburg Ohio. The gas was subsequently loaded and stored on an IN/USSystems Inc. Trisorber. MicroScint 20 scintillation cocktail wasobtained from Packard Instrument Co.

Protocol for Ex-Vivo Platelet Aggregation in Cynomolgus Whole Blood DrugAdministration and Blood Collection:

Conscious chaired cynomolgus monkeys are allowed to equilibrate for 30min. A needle catheter is inserted into a brachial vein for infusion oftest drugs. Another needle catheter is inserted into the other brachialor saphenous vein and used for blood sampling. In those experimentswhere the compound is administered orally only one catheter is used. Abaseline blood sample (1-2 ml) is collected in vacutainer tubescontaining a thrombin inhibitor CVS 2139 (100 μg/0.1 ml saline) as ananticoaculant. The drug is then infused intravenously over a period of30 min. Blood samples (1 ml) are collected at 5, 10, 20, 30 min duringand 30, 60, 90 min after termination of the drug infusion. In POexperiments the animals are dosed with the drug using a gavage cannula.Blood samples are collected at 0, 30, 60, 90, 120, 180, 240, 300, 360min after dosing. 0.5 ml of the blood is used for whole bloodaggregation and the other 0.5 ml is used for determining the plasmaconcentration of the drug or its metabolites. Aggregation is performedimmediately after collection of the blood sample as described below.

Whole Blood Aggregation:

A 0.5 ml blood sample is added to 0.5 ml of saline and warmed to 37° C.in a Chronolog whole blood aggregometer. Simultaneously, the impedanceelectrode is warmed in saline to 37° C. The blood sample with a stir baris place in the heating block well, the impedance electrode is placed inthe blood sample and the collection software is started. The software isallowed to run until the baseline is stabilized and then a 20 Ωcalibration check is performed. 20 Ω is equal to 4 blocks on the graphicproduced by the computer software. The agonist (haTRAP) is added by anadjustable volume pipette (5-25 μl) and the aggregation curve isrecorded for 10 minutes. Maximum aggregation in 6 minutes followingagonist is the value recorded.

In vitro Platelet Aggregation Procedure:

Platelet aggregation studies were performed according to the method ofBednar et al. (Bednar, B., Condra, C., Gould, R. J., and Connolly, T.M., Throm. Res., 77:453-463 (1995)). Blood was obtained from healthyhuman subjects who were aspirin free for at least 7 days by venipunctureusing ACD as anticoagulant. Platelet rich plasma was prepared bycentrifugation at 100×g for 15 minutes at 15 deg C. Platelets werepelleted at 3000×g and washed twice in buffered saline containing 1 mMEGTA and 20 μg/ml apyrase to inhibit aggregation. Aggregation wasperformed at room temperature in buffered saline supplemented with 0.2mg/ml human fibrinogen. Test compound and platelets were preincubated in96-well flat-bottom plates for 60 minutes. Aggregation was initiated byadding 0.3 μM haTRAP or 0.1 U/ml thrombin and rapidly vortexing themixture using a Lab Line Titer Plate Shaker (speed 7). Percentaggregation was monitored as increasing light transmittance at 405 nm ina Spectromax Plate Reader.

In Vivo Antitumor Procedure:

Tests in the human breast carcinoma model in nude mouse are conductedaccording to the procedure reported in S. Even-Ram et. al., NatureMedicine, 4, 8 (1988), p. 909-914.

Using the test procedures described above, in the in vitro thrombinreceptor antagonist assay, compounds of the invention were found to haveIC₅₀ values (i.e., the concentration at which a 50% inhibition ofthrombin receptor was observed) in the range of about 1 to about 2000nM, with preferred compounds having IC₅₀ values in the range of about 1to about 100 nM.

While the present invention has been described in conjunction with thespecific embodiments set forth above, many alternatives, modificationsand variations thereof will be apparent to those of ordinary skill inthe art. All such alternatives, modifications and variations areintended to fall within the spirit and scope of the present invention.

1. A compound represented by the structural formula

or a pharmaceutically acceptable salt thereof, wherein: R is 1 to 3substituents independently selected from the group consisting of H,C₁-C₆ alkyl, halogen, hydroxy, amino, (C₁-C₆)alkyl-amino,(C₁-C₆)-dialkylamino, (C₁-C₆)alkoxy, —COR¹⁶, —COOR¹⁷, —SOR¹⁶, —SO₂R¹⁶,—SO₂NR¹⁷R¹⁸, —NR¹⁷SO₂R¹⁸, —NR¹⁶COR^(16a), —NR¹⁶COOR^(16a), —NR¹⁶CONR⁴R⁵,fluoro-(C₁-C₆)alkyl, difluoro(C₁-C₆)alkyl, trifluoro(C₁-C₆)alkyl, C₃-C₆cycloalkyl, aryl(C₁-C₆)alkyl, hydroxy(C₁-C₆)alkyl, amino-(C₁-C₆)-alkyl,aryl and thio(C₁-C₆)alkyl; R¹ and R² are independently selected from thegroup consisting of H, C₁-C₆ alkyl, fluoro(C₁-C₆)alkyl,difluoro(C₁-C₆)alkyl, trifluoro-(C₁-C₆)alkyl, C₃-C₆ cycloalkyl, C₂-C₆alkenyl, aryl(C₁-C₆)alkyl, hydroxy-(C₁-C₆)alkyl, amino(C₁-C₆)alkyl, aryland thio(C₁-C₆)alkyl; or R¹ and R² together form an ═O group; R³ is H,hydroxy, C₁-C₆alkoxy, aryloxy, aryl(C₁-C₆)alkyloxy, heteroaryloxy,heteroaryl(C₁-C₆)alkyloxy, (C₃-C₆)cycloalkyloxy, —SOR¹⁶, —SO₂R¹⁷,—SO₂NR¹⁸R¹⁹, —SR¹⁸, —SO₃H, —C(O)OR¹⁷, —C(O)NR¹⁸R¹⁹, —OC(O)R³²,—OC(O)NR³³R³⁴, —(CR³³R³⁴)_(n)OR³², —NR⁴R⁵, —NR³³COOR³², —NR³³COR³²,—NR³³S(O)₂R³², —NR³³CONR³³R³⁴, —NR³³S(O)₂NR³³R³⁴, —(CR³³R³⁴)_(n)NR⁴R⁵,—(CR³³R³⁴)_(n)NR³³COOR³², —(CR³³R³⁴)_(n)NR³³COR³²,—(CR³³R³⁴)_(n)NR³³S(O)₂R³², —(CR³³R³⁴)_(n)NR³³CONR³³R³⁴,—(CR³³R³⁴)_(n)NR³³S(O)₂NR³³R³⁴, (C₁-C₆)alkyl, halogen, C₃-C₆ cycloalkyl,C₂-C₆ alkenyl, —CN, aryl, heteroaryl, heterocycloalkyl, —P(O)(OR⁷)₂ or(C₁-C₆)alkyl substituted by 1 to 3 substituents independently selectedfrom the group consisting of halogen, —OH, —NH₂, aryl, —COOH, —SO₃H,thio and (C₁-C₆)alkylthio; n is 1, 2, 3 or 4; n1 and n2 areindependently 0-3, provided both are not 0; Het is a mono-, bi- ortricyclic heteroaromatic group of 5 to 14 atoms comprised of 1 to 13carbon atoms and 1 to 4 heteroatoms independently selected from thegroup consisting of N, O and S, wherein a ring nitrogen can form anN-oxide or a quaternary group with a C₁-C₄ alkyl group, wherein Het isattached to B by a carbon atom ring member, and wherein the Het group issubstituted by 1 to 4 substituents, W, independently selected from thegroup consisting of C₁-C₆ alkyl; —NR⁴R⁵; —NHCOR²⁶; —NHSO₂R¹⁶; R²¹-aryl;aryl wherein adjacent carbons form a ring with a methylenedioxy group;and R²¹-heteroaryl; R⁴ and R⁵ are independently selected from the groupconsisting of H, C₁-C₆ alkyl, phenyl, benzyl and C₃-C₆ cycloalkyl, or R⁴and R⁵ together are —(CH₂)₃—, —(CH₂)₄—, —(CH₂)₅— or —(CH₂)₂NR⁷—(CH₂)₂—and form a ring with the nitrogen to which they are attached; R⁷ is H or(C₁-C₆)alkyl; R⁸, R¹⁰ and R¹¹ are independently selected from the groupconsisting of R¹ and —OR¹; R⁹ is H, OH, —NR⁴R⁵, C₁-C₆alkoxy, halogen orhalo(C₁-C₆)alkyl; B is —(CH₂)_(n) ₃ — or cis or trans —(CH₂)_(n) ₄CR¹²═CR^(12a)(CH₂)_(n) ₅ , wherein n₃ is 0-5, n₄ and n₅ areindependently 0-2, and R¹² and R^(12a) are independently selected fromthe group consisting of H, C₁-C₆ alkyl and halogen; R¹⁶ and R^(16a) areindependently selected from the group consisting of C₁-C₆ alkyl, phenyland benzyl; R¹⁷, R¹⁸ and R¹⁹ are independently selected from the groupconsisting of H, C₁-C₆alkyl, phenyl and benzyl; R²¹ is 1 to 3substituents independently selected from the group consisting of H,—CF₃, —OCF₃, halogen, —NO₂, —CN, C₁-C₆ alkyl, C₁-C₆ alkoxy, —NH₂,(C₁-C₆)-alkyl-amino, di-((C₁-C₆)alkyl)amino, amino(C₁-C₆)alkyl,(C₁-C₆)-alkylamino(C₁-C₆)alkyl, di-((C₁-C₆)alkyl)-amino(C₁-C₆)alkyl,hydroxy-(C₁-C₆)alkyl, —COOR¹⁷, —COR¹⁷, —CONR²⁴R²⁵, —NHCOR⁶, —NHSO₂R¹⁶,—NHSO₂CH₂CF₃, —SO₂NR²⁴R²⁵, —NR²⁹C(O)NR²⁴R²⁵, —SO₂R³⁰, —P(O)(OR²⁹)₂,aryl, aryl(C₁-C₆)alkyl, heteroaryl, heterocycloalkyl, and —CR²⁹(═NOR²⁸);R²² is —COR²³, —S(O)R³¹, —S(O)₂R³¹, —SO₂NR²⁴R²⁵ or —COOR²⁷; R²³ ishalo(C₁-C₆)alkyl; C₂-C₆ alkenyl; halo(C₂-C₆)alkenyl; C₂-C₆ alkynyl;C₃-C₇-cycloalkyl; (C₃-C₇)cycloalkyl(C₁-C₆)alkyl; (C₃-C₇)cycloalkylsubstituted by 1 to 3 substituents selected from the group consisting ofhalo, (C₁-C₃)alkoxy(C₁-C₃)alkyl, hydroxy and C₁-C₆ alkoxy; aryl;aryl(C₂-C₆)alkyl; heteroaryl; heterocycloalkyl; (C₁-C₆)alkyl substitutedby 1-3 substituents independently selected from —COOH and —SO₃H; or

wherein R³⁵ and R³⁶ are independently selected from the group consistingof H, alkyl, or R³⁷-substituted C₁-C₆ alkyl, wherein R³⁷ is selectedfrom the group consisting of HO—, HS—, CH₂S—, —NH₂, phenyl,p-hydroxyphenyl and indolyl; R²⁴ and R²⁵ are independently selected formthe group consisting of H, C₁-C₆ alkyl, halo(C₁-C₆)alkyl, C₂-C₆ alkenyl,halo(C₂-C₆)alkyl, C₂-C₆ alkynyl, aryl, aryl-(C₁-C₆)alkyl,C₃-C₇-cycloalkyl, halo(C₃-C₇)cycloalkyl, (C₁-C₃)alkoxy(C₁-C₃)-alkyl,hydroxy and C₁-C₆ alkoxy; R²⁶ is C₃-C₇-cycloalkyl, aryl,aryl-(C₁-C₆)alkyl, heteroaryl, heteroaryl-(C₁-C₆)alkyl or(C₁-C₆)alkylamino; R²⁷ is C₁-C₆alkyl, phenyl, benzyl,(C₁-C₃)alkoxy(C₁-C₃)-alkyl, (C₃-C₇)-cycloalkyl, carboxy(C₁-C₆)alkyl,sulfo(C₁-C₆)alkyl, or (C₁-C₆)alkyl substituted by NR¹⁸R¹⁹ and carboxy;R²⁸ is H, C₁-C₆ alkyl, phenyl, benzyl or (C₁-C₃)alkoxy(C₁-C₃)alkyl; R²⁹and R³⁰ are independently selected from the group consisting of H andC₁-C₆ alkyl; R³¹ is (C₁-C₆)alkyl; halo(C₁-C₆)alkyl; C₂-C₆ alkenyl;halo(C₂-C₆)alkyl; C₂-C₆ alkynyl; C₃-C₇-cycloalkyl; (C₃-C₇)cycloalkylsubstituted by 1 to 3 substituents selected from the group consisting ofhalo, (C₁-C₃)alkoxy(C₁-C₃)alkyl, hydroxy and C₁-C₆ alkoxy; aryl;aryl(C₁-C₆)alkyl; heteroaryl; heterocycloalkyl; (C₁-C₆)alkyl substitutedby 1-3 substituents independently selected from —COOH and —SO₃H; or(C₁-C₆)alkoxy; R³² is R³⁵—(C₁-C₆)alkyl, R³⁵—(C₃-C₇)cycloalkyl,R³⁵—(C₂-C₆)alkenyl, R³⁵—(C₂-C₆)-alkynyl or R³⁵-aryl, wherein R³⁵ is 1 or2 substituents independently selected from the group consisting of H,—COOH, —NH₂, —SO₃H, ═O and ═NOR²⁸; and R³³ and R³⁴ are independentlyselected from the group consisting of H, (C₁-C₆)alkyl andC₃-C₇-cycloalkyl.
 2. A compound of claim 1 wherein the sum of n1 and n2is
 3. 3. A compound of claim 1 wherein R¹, R¹⁰ and R¹¹ are independentlyselected from the group consisting of H and C₁-C₆ alkyl; R² and R⁸ areeach hydrogen; and R⁹ is H, OH or C₁-C₆ alkoxy.
 4. A compound of claim 1wherein R is H, halogen, OH, C₁-C₆ alkyl, C₁-C₆ alkoxy or amino.
 5. Acompound of claim 1 wherein B is —CH═CH—.
 6. A compound of claim 1wherein Het is pyridyl, W-substituted pyridyl, quinolyl or W-substitutedquinolyl.
 7. A compound of claim 6 wherein W is —NR⁴R⁵, —NHCOR²⁶,—NHSO₂R¹⁶, R²¹-aryl or heteroaryl.
 8. A compound of claim 7 wherein R²¹is 1 to 3 substituents independently selected from the group consistingof H, —CF₃, —OCF₃, halogen, —CN, C₁-C₆ alkyl, C₁-C₆ alkoxy, —NH₂ and—CR²⁹(═NOR²⁸).
 9. A compound of claim 1 wherein R³ is H, hydroxy,C₁-C₆alkoxy, halogen, C₃-C₆ cycloalkyl, —CN, (C₁-C₆)alkyl, —COOR¹⁷ or—NR⁴R⁵.
 10. A compound of claim 1 wherein R²² is —COR²³, —S(O)₂R³¹ or—COOR²⁷.
 11. A compound of claim 10 wherein R²³ is C₃-C₇-cycloalkyl;(C₃-C₇)cycloalkyl substituted by 1 to 3 substituents selected from thegroup consisting of halo, (C₁-C₃)alkoxy(C₁-C₃)alkyl, hydroxy and C₁-C₆alkoxy; (C₃-C₇)cycloalkyl(C₁-C₆)alkyl; aryl; or aryl(C₂-C₆)alkyl.
 12. Acompound of claim 11 wherein R²³ is C₃-C₇-cycloalkyl;(C₃-C₇)cycloalkyl(C₁-C₆)alkyl or aryl-(C₂-C₆)alkyl.
 13. A compound ofclaim 10 wherein R³¹ is (C₁-C₆)alkyl, C₃-C₇-cycloalkyl, aryl oraryl(C₁-C₆)alkyl.
 14. A compound of claim 10 wherein R²⁷ is C₁-C₆alkyl,phenyl, benzyl, (C₁-C₃)alkoxy(C₁-C₃)alkyl or (C₃-C₇)cycloalkyl.
 15. Acompound of claim 1 selected from the group consisting of compounds ofthe formula

wherein W and R²² are as defined in the table: W R²²

—CO₂Et

—CO₂Et

—CO₂Et

—CO₂Et

—CO₂Et

—CO₂Et

—CO₂Et

—CO₂Et

—CO₂Et

—CO₂CH₂CH₂OMe

and compounds of the formula

wherein W is as defined in the following table: W


16. A pharmaceutical composition comprising an effective amount of atleast one compound of claim 1 and a pharmaceutically acceptable carrier.17. A method of inhibiting thrombin receptors comprising administeringto a mammal in need of such treatment an effective amount of at leastone compound of claim
 1. 18. A method of treating thrombosis,atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia,heart failure, myocardial infarction, glomerulonephritis, thromboticstroke, thromboembolytic stroke, peripheral vascular diseases,inflammatory diseases, respiratory diseases, cerebral ischemia orcancer, comprising administering to a mammal in need of such treatmentan effective amount of at least one compound of claim
 1. 19. A compoundselected from the group consisting of compounds of the formula

wherein W and Z are as defined in the following table: W Z

—S—

—S(O)—

—O—

—O—

—O—

—O—

—O—

—O—

—NH—

—N(CH₃)—